'Biological medicines' presentation slideshows

PhAMA Position on Biosimilar Medicines

PhAMA Position on Biosimilar Medicines. Ms. Leah Goodman. Contents. An Overview - Biological Medicines and their Regulatory Framework. PhAMA Position and Recommendation on Biosimilars. Key Messages. An Overview - Biological Medicines and their Regulatory Framework.

203 views • 19 slides

Biosimilar & Patents - Challenges for Research & Analysis

173 views • 15 slides

Global Oncology Biosimilars Market Demand, Growth, 2014-18

Get access to detailed report at: http://www.researchbeam.com/global-oncology-biosimilars-2014-2018-market Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars.

507 views • 7 slides